NADPH-oxidases as potential pharmacological targets for thrombosis and depression comorbidity

Area of Science:

• Neurocardiology
• Oxidative Stress Biology
• Pharmacology

Background:

• Cardiovascular diseases (CVD) and mental disorders frequently co-occur.
• Oxidative stress, driven by reactive oxygen species (ROS), is implicated in the pathophysiology of both brain and cardiovascular conditions.
• Nicotinamide adenine dinucleotide phosphate oxidase (NOX) is a primary enzyme generating superoxide ROS.

Purpose of the Study:

• To review the role of NOX activation in thrombosis and depression.
• To discuss the therapeutic potential of NOX inhibitors for CVD and brain disorders.
• To explore novel therapeutic strategies for the comorbidity of thrombosis and depression.

Main Methods:

• Literature review of recent findings on NOX activation.
• Analysis of NOX inhibitor efficacy in preclinical and clinical studies.
• Synthesis of information on the link between NOX, oxidative stress, and disease pathophysiology.

Main Results:

• NOX activation is a key factor in the development of thrombosis and depression.
• NOX inhibitors demonstrate promising therapeutic effects in models of CVD and neurological disorders.
• Targeting NOX pathways may offer a unified approach to managing comorbid conditions.

Conclusions:

• Understanding NOX-mediated oxidative stress is crucial for addressing the CVD-mental disorder comorbidity.
• NOX inhibitors represent a viable therapeutic avenue for treating thrombosis and depression.
• Further research into NOX inhibition could lead to innovative treatments for these prevalent, interconnected diseases.